Switching entecavir tablets to melt-in-mouth form after liver transplant
Part of Digestive system, Infections clinical trials.
This trial tests switching from standard entecavir pills to a different form (ODT, which dissolves in your mouth) for people who have had a stable liver transplant for hepatitis B. It aims to see if the new form works just as well and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Must be 19 years or older.
- You had a liver transplant for hepatitis B and your new liver has been working well for at least 1 year.
- Your blood tests show no active hepatitis B (HBsAg negative, HBV DNA undetectable).
- You have been taking entecavir for at least 1 year to prevent hepatitis B from coming back.
- Your tacrolimus levels are between 3-10 ng/mL (a specific range for your anti-rejection medicine).
- You do not have active hepatitis C, HIV, severe kidney problems, or a history of allergic reaction to entecavir.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if switching your current hepatitis B antiviral to Tenofovir Alafenamide (TAF) keeps your new liver working well with fewer side effects. It is for people who had a liver transplant due to hepatitis B and have stable liver function for at least a year.
This trial studies switching people with chronic hepatitis B from entecavir (ETV) to tenofovir alafenamide (TAF). It may help if you feel your current entecavir treatment isn’t working well enough or is inconvenient.
This trial tests whether giving the antiviral drug entecavir before or at the first sign of hepatitis B reactivation can prevent liver problems in gastrointestinal cancer patients who are inactive hepatitis B carriers and are starting chemotherapy or immunotherapy.
This trial tests whether adding a short course of interferon to standard antiviral medicine (entecavir) helps younger children with chronic hepatitis B whose immune system has not yet started fighting the virus. It aims to see if this combination can lead to a functional cure.
This trial compares two treatments for young children (ages 3–6) with active chronic hepatitis B: entecavir alone versus entecavir plus a short course of pegylated interferon. The goal is to see if adding interferon helps control the infection better.
This trial tests if switching from bulevirtide to brelovitug can help people with chronic hepatitis D (CHD). It is for adults who have been on bulevirtide for at least 6 months and still have detectable virus.
Hear when a new Liver Transplant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.